Bone Biologics Corp Warrants
BBLGW
3 hedge funds and large institutions have $358K invested in Bone Biologics Corp Warrants in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
1.1% less ownership
Funds ownership: 1.1% → 0% (-1.1%)
33% less capital invested
Capital invested by funds: $537K → $358K (-$179K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.06K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $356K | -$1.06K | -100 | -0.3% |
|
2
UBS Group
Zurich,
Switzerland
| $1.14K | – | – | – |
|
3
Bank of America
Charlotte,
North Carolina
| $800 | – | – | – |
|
BBLGW Hedge Fund Activity: Q3 2025 in Review
3 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q3 2025, worth a combined $358K — down 33% from $537K a quarter earlier.
Fund positioning in BBLGW was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Citadel Advisors, cutting an estimated $1.06K.
- 3 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $358K of Bone Biologics Corp Warrants stock for Q3 2025, down 33% quarter-over-quarter.
- 0 funds opened new Bone Biologics Corp Warrants positions in Q3 2025 and 0 closed out.
- The largest Bone Biologics Corp Warrants seller in Q3 2025 was Citadel Advisors, an estimated $1.06K sold.
Based on aggregated 13F filings for Q3 2025.